Emergent BioSolutions Inc.

NYSE:EBS Rapporto sulle azioni

Cap. di mercato: US$481.2m

Emergent BioSolutions Crescita futura

Future criteri di controllo 4/6

Si prevede che i ricavi di Emergent BioSolutions diminuiranno a 0.7% all'anno, mentre si prevede che i suoi utili annuali cresceranno a 98.5% all'anno. Si prevede che l'EPS crescerà di 98.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà 28.4% in 3 anni.

Informazioni chiave

98.5%

Tasso di crescita degli utili

98.6%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.4%
Tasso di crescita dei ricavi-0.7%
Rendimento futuro del capitale proprio28.4%
Copertura analitica

Low

Ultimo aggiornamento07 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth

Nov 09
Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic

Nov 08

Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

Oct 04

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Sep 16
Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Aug 18

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Aug 02
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process

Jul 15

Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround

May 10

New CEO Appointment A Clear Positive For Emergent BioSolutions

Feb 27

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Dec 18

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Nov 23

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Aug 23

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Aug 14

Emergent BioSolutions: Making A Big Bet On Narcan

Jul 21

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

Previsioni di crescita degli utili e dei ricavi

NYSE:EBS - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20261,08113N/AN/A1
12/31/20251,196491661831
12/31/20241,108-182146601
9/30/20241,126-209138171N/A
6/30/20241,102-5873177N/A
3/31/20241,185-565-138-85N/A
12/31/20231,049-760-264-206N/A
9/30/20231,103-778-216-146N/A
6/30/20231,072-602-602-280N/A
3/31/2023974-394-523-181N/A
12/31/20221,118-212-394-34N/A
9/30/20221,49133-180201N/A
6/30/20221,58188127292N/A
3/31/20221,75715878279N/A
12/31/20211,77422096320N/A
9/30/20211,65322723237N/A
6/30/20211,709299121326N/A
3/31/20211,706387300483N/A
12/31/20201,577306385537N/A
9/30/20201,333167262413N/A
6/30/20201,259170184305N/A
3/31/20201,1086841141N/A
12/31/20191,1065591188N/A
9/30/20191,0164-181-100N/A
6/30/2019878-18-1577N/A
3/31/20198554266148N/A
12/31/201878263-3042N/A
9/30/2018706100221285N/A
6/30/2018681113N/A146N/A
3/31/201856267N/A165N/A
12/31/201756183N/A208N/A
9/30/201751981N/A118N/A
6/30/201751268N/A110N/A
3/31/201750361N/A54N/A
12/31/201648963N/A55N/A
9/30/201649773N/A70N/A
6/30/201651294N/A148N/A
3/31/2016529125N/A153N/A
12/31/201548991N/A43N/A
9/30/201547879N/A93N/A
6/30/201545759N/A67N/A
3/31/201546035N/A76N/A
12/31/201440454N/A112N/A
9/30/201440022N/A69N/A
6/30/201435114N/A50N/A
3/31/201432419N/A72N/A
12/31/201331331N/A97N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che EBS diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che EBS diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede EBS diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di EBS diminuiranno nei prossimi 3 anni ( -0.7% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di EBS diminuiranno nei prossimi 3 anni ( -0.7% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di EBS sarà elevato tra 3 anni ( 28.4 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y